MeSH tree: N04.761.559
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab ...
6 hours ago
0
3
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to Phase II clinical ...
17 hours ago
0
8
Women suffering from pelvic organ prolapse might be best served by surgery that preserves their uterus rather than removing it, a landmark clinical trial reports.
Jul 21, 2026
0
4
When the BBC presenter Lauren Laverne revealed she has smoldering myeloma, the diagnosis sounded more alarming than it is. Her situation is more subtle and nuanced than the word "myeloma" suggests.
Jul 21, 2026
0
2
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration ...
Jul 16, 2026
0
6
A new study from University Hospitals Connor Whole Health reports that an insurance-supported integrative oncology program resulted in clinically meaningful improvements in cancer-related symptoms like pain, stress, anxiety, ...
Jul 13, 2026
0
2
Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine ...
Jul 7, 2026
0
5
For patients with clear-cell renal cell carcinoma, pembrolizumab-belzutifan yields significantly higher disease-free survival, according to a study published in the July 2 issue of the New England Journal of Medicine.
Jul 6, 2026
0
3
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according ...
Jul 2, 2026
0
3
Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically ...
Jul 1, 2026
0
5
